VALVOSOFT®, the First Non-Invasive Treatment for Severe Symptomatic Aortic Stenosis (sSAS) from Cardiawave Receives CE Marking
Cardiawave, a pioneering medtech company developing non-invasive ultrasound therapy (NIUT) for aortic stenosis, has received CE Certificate for Valvosoft®, the world’s first non-invasive therapeutic alternative to treat Severe Symptomatic Aortic Stenosis (sSAS), a serious, degenerative and fast-growing disease due to population aging, which remains without a solution for many patients around the world.
Cardiawave Strengthens Leadership with Appointment of Jonathan Freeman as Board Chairman
Cardiawave, a pioneering medtech company developing non-invasive ultrasound therapy (NIUT) for aortic stenosis, today announced the appointment of Jonathan Freeman, PhD, as Chairman of its Board of Directors.
Cardiawave Announces the Publication in The Lancet of First-In-Human Clinical Studies Results With 40 Aortic Stenosis Patients Treated With Its Innovative Non-invasive Ultrasound Therapy (NIUT)
Cardiawave SA, a French Medtech which has developed an innovative Non-Invasive focused Ultrasound Therapy device for the treatment of calcific aortic stenosis, announced today the publication of results from its First-In-Human (FIH) clinical studies on 40 patients suffering from CAS treated with its NIUT in The Lancet and the completion of the enrollment of 60 patients in its “Valvosoft® pivotal study”.
Cardiawave announces French National Agency for the Safety of Medicines and Health Products (ANSM) green light to launch VALVOSOFT® Pivotal Study in France
Cardiawave SA, a deeptech medical device manufacturer that has developed VALVOSOFT® a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults, today announced the authorization by the French National Agency for the Safety of Medicines and Health Products to proceed with a new clinical study in France.
